Navigation Links
TNI BioTech Acquires Exclusive License To The Portfilio Of Patents Of Dr Ian S. Zagon, Dr. Patricia J. McLauglin And Dr. Jill Smith From The Penn State Research Foundation
Date:2/1/2013

 system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

TNI BioTech's proprietary technology, therapies and patents include the treatment of a wide range of cancers. Their most advanced clinical program involves immunotherapy with Methionine Enkephalin (MENK) also termed Opioid Growth Factor (OGF), which has been shown to stimulate the immune system even in patients with advanced cancer.

Even though TNI BioTech considers any condition that results in altered-immune response a target for investigation, they plan to pursue additional investigations for low dose naltrexone and/or MENK as valuable candidates in the treatment of the following:

  • Autoimmune states such as Crohn's disease, multiple sclerosis and rheumatoid arthritis
  • As an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery
  • As an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV or patients with AIDS, in combination with retroviral drug therapy

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks
'/>"/>

SOURCE TNI BioTech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chief Medical Officers in Biotechs Finally Have Their Own Conference
2. BioSpace Releases 2013 Life Sciences / Biotech Employment Outlook
3. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
4. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
5. Biotechnology guaranteed US$ 100 K to average Brazilian corn growers in four years, according to ABRASEM
6. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
7. 2012 Cotton Biotechnology Award Recipients
8. Ganeden Biotech® Moves Its State-Of-The-Art Lab To Its World Headquarters In Cleveland
9. Biotechnology: Global Industry Guide
10. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... Dec. 30 Accuray Incorporated,(Nasdaq: ARAY ), a ... president and chief executive officer, Euan S. Thomson, Ph.D., is,scheduled ... in San,Francisco, on Wednesday, January 14, 2009 at 11:30 a.m. ... live webcast of the presentation will be available online from ...
... Israel, JERSEY CITY, New Jersey and PHILADELPHIA, ... ROSG),the leading developer of microRNA-based molecular diagnostics, ... test, miRview(TM) meso. The,test is now commercially ... , To order ...
... Thickness and Darkness of EyelashesIRVINE, Calif., Dec. 26 ... the U.S. Food and Drug Administration (FDA) has approved ... for hypotrichosis of the eyelashes. Eyelash hypotrichosis is ... LATISSE(TM) is the first and only science-based treatment ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at 27th Annual JP Morgan Healthcare Conference 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 2Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 4Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 6Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 7Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 8Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 9
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... Arctic is happening at a greater rate than other ... to continue in the future. As a result, ... sea level rise can be expected to continue. ... demonstrates for the first time the pervasive nature of ...
... Jan. 12, 2009 The 2009 winners of the ... Adusumilli, M.D. and Lee Goodglick, Ph.D. The $100,000 grants ... and the role of estrogen in lung cancer tumors, ... in lung cancer at Memorial Sloan-Kettering Cancer Center in ...
... new way to inhibit a molecule that is critical ... in the January 16th issue of the journal ... antiretroviral therapeutics that are likely to complement existing therapies ... Infection of human cells with HIV-1 requires multiple events ...
Cached Biology News:Arctic heats up more than other places 2National Lung Cancer Partnership and LUNGevity Foundation announce 2009 grant recipients 2Mutant host cell protein sequesters critical HIV-1 element 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Goat polyclonal to Als2 ( Abpromise for all tested applications). entrezGeneID: 57679 SwissProtID: Q96Q42...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: